ArticleNature2024
SOX17 enables immune evasion of early colorectal adenomas and cancers.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
40.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 96 citations in OpenAlex.
- Organoids: Current Applications and Future Directions.MedComm · 2026Review
- Article
- Mechanism-Driven Diagnostic Development: A Specimen-Aware Framework Illustrated by Colorectal Cancer and Solid Tumours.Cancers · 2026Review
- Review
- Lineage plasticity driven by GATA6 loss fuels colorectal cancer metastasis.Cell stem cell · 2026Article
- High SOX17 expression is correlated with favorable prognosis and CD8(+) TILs expression in patients with pancreatic cancer after curative resection.Translational oncology · 2026Article
- SOX5 Orchestrates Malignant Evolution via Promoter-Centric Chromatin Remodeling in MYC-Driven B-Cell Lymphoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications.Journal of hematology & oncology · 2026Review
- Progressive intestinal tumor cell plasticity, Myc activation, and loss of Lgr5Science advances · 2026Article
- Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases.Cell death & disease · 2026Article
- Colorectal cancers with distinct metastatic potential trigger divergent early T cell responses.bioRxiv : the preprint server for biology · 2026Article
- LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer.Cancer discovery · 2026Article
- Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy.MedComm · 2026Review
- The integrated clinico-scientific system for gastrointestinal diseases combining Chinese and Western medicine.Journal of translational medicine · 2026Article
- Dynamic Reprogramming of PDGFRA-Expressing Stromal Cells Facilitates WNT-Driven Transformation by Promoting a Fetal-Like State in the Intestinal Epithelium.Cancer research · 2026Article
- Article
- USP21 drives immune evasion in colorectal cancer via deubiquitination and stabilization of β-catenin.Cellular & molecular immunology · 2026Article
- Berberine impedes the DNA damage repair to inhibit colorectal cancer by regulating the SOX17/TCF4/PIM3 axis.Molecular genetics and genomics : MGG · 2026Article
- Review
- Tumour-associated high endothelial venules drive portal-specific immune evasion in lymph nodes via ALOX12.Nature communications · 2026Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 5 institutions in 1 country.
Norihiro GotoDepartment of Biology, The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA.
Peter M K Westcott *Department of Biology, The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-9436-4857
Saori Goto *Department of Biology, The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-7811-7397
Shinya ImadaDepartment of Biology, The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA.
Martin S TaylorDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1560-9276
George EngDepartment of Biology, The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA.
Jonathan BravermanDepartment of Biology, The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA.
Vikram DeshpandeDepartment of Pathology, Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA, USA.
Tyler JacksDepartment of Biology, The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-5785-8911
Judith AgudoDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. judith_agudo@dfci.harvard.edu.ORCID 0000-0002-3576-3169
Ömer H YilmazDepartment of Biology, The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA. ohyilmaz@gmail.com.ORCID 0000-0002-7577-4612
Harvard University · USMassachusetts Institute of Technology · USBroad Institute · USCold Spring Harbor Laboratory · USInnovative Genomics Institute · US
Funding
Single-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI David A Tuveson · 1987 to 2026
$118.9MVIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9MProject 2U54CA224068 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CORCORAN, RYAN BRUCE, FLAHERTY, KEITH T · 2017 to 2021
$6.3MEffects of inflammaging on intestinal epithelial cells and aspirin chemoprevention.R01CA257523 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T, STAPPENBECK, THADDEUS S · 2021 to 2025
$3.7MMechanisms of HIV-associated epithelialintestinal stem cell (ISC) dysfunctionR01DK126545 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI KLOVERPRIS, HENRIK, KWON, DOUGLAS · 2020 to 2024
$3.6MImmunometabolic regulation of CD8+ T cell mediated intestinal epithelial cell death in people with HIV (PWH)R01DK133919 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Douglas Kwon, Omer Yilmaz · 2022 to 2026
$3.5MDeveloping high-throughput genetic perturbation strategies for single cells in cancer organoidsU01CA250554 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BERGER, BONNIE, YILMAZ, OMER · 2020 to 2022
$2.8MImpact of fasting on intestinal stem cells and cancerR01CA245314 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Omer Yilmaz · 2020 to 2026
$2.3MEngineering dendritic cells to target islet antigen to pro-tolerogenic subsets for prevention and treatment of Type 1 DiabetesR01DK132544 · NIDDK · DANA-FARBER CANCER INST · PI Judith Agudo Cantero · 2022 to 2026
$2.2MElucidating structural, mechanistic, and allosteric determinants of mTOR Complex 2 (mTORC2) signaling.K08DK129824 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI TAYLOR, MARTIN S · 2021 to 2025
$853kMechanisms and strategies to rescue suboptimal T cell priming in colon cancerK22CA279501 · NCI · COLD SPRING HARBOR LABORATORY · PI WESTCOTT, PETER MAXWELL KIENITZ · 2023 to 2025
$603kRegulation of the Intestinal Stem Cell Niche in AgingK99AG045144 · NIA · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI YILMAZ, OMER · 2013 to 2014
$275kNCI NIH HHS F32 CA254314NCI NIH HHS K22 CA279501NCI NIH HHS P30 CA014051NCI NIH HHS P30 CA045508NCI NIH HHS R01 CA245314NCI NIH HHS R01 CA257523NCI NIH HHS U01 CA250554NCI NIH HHS U54 CA224068NIA NIH HHS K99 AG045144NIA NIH HHS K99 AG076987NIDDK NIH HHS K08 DK129824NIDDK NIH HHS R01 DK126545NIDDK NIH HHS R01 DK132544NIDDK NIH HHS R01 DK133919
Abstract
A hallmark of cancer is the avoidance of immune destruction. This process has been primarily investigated in locally advanced or metastatic cancer
Indexed as
AdenomaColorectal NeoplasmsImmune EvasionSOXF Transcription FactorsAdenomatous Polyposis Coli ProteinAnimalsCD8-Positive T-LymphocytesChromatinDisease ProgressionEndodermGene Expression ProfilingHMGB ProteinsHumansInterferon-gammaMiceMutationAdenomatous Polyposis Coli Proteinadenomatous polyposis coli protein, mouseChromatinHMGB ProteinsHras protein, mouseInterferon-gammaLGR5 protein, humanProto-Oncogene Proteins p21(ras)Receptors, G-Protein-CoupledSOX17 protein, humanSox17 protein, mouseSOXF Transcription FactorsTrp53 protein, mouseTumor Suppressor Protein p53
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.